Neuren Pharmaceuticals Limited

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Neuren Pharmaceuticals Limited sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 2 currently recruiting 7 completed early-phase tilt top decile by trial count

Neuren Pharmaceuticals Limited: 10 sponsored US clinical trials, 2 recruiting.

Neuren Pharmaceuticals Limited sponsors 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. 2 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Phelan-McDermid Syndrome, with 1 trials.

Top-decile sponsor footprint

Neuren Pharmaceuticals Limited ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 3

An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

NCT07593391
RECRUITING Phase 3

A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

NCT07281079
COMPLETED Phase 2

An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)

NCT05025332
COMPLETED Phase 2

An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)

NCT05025241
COMPLETED Phase 2

A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

NCT02715115
TERMINATED Phase 2

A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)

NCT02100150
COMPLETED Phase 2

A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

NCT01894958
COMPLETED Phase 2

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

NCT01703533
COMPLETED Phase 2

Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC

NCT01366820
COMPLETED Phase 2

Study of NNZ-2566 in Patients With Traumatic Brain Injury

NCT00805818

Phase Distribution

PhaseTrial count
Phase 2 8
Phase 3 2

Therapeutic Areas

Phelan-McDermid Syndrome 1
Brain Injuries 1

What is open in the Neuren Pharmaceuticals Limited pipeline

2 recruiting of 10 indexed (20% open); 7 completed (70%).

Phase mix: 2 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Phelan-McDermid Syndrome (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Neuren Pharmaceuticals Limited: open-pipeline peers nationwide

Peers matched on 10 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

Neuren Pharmaceuticals Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4681012 0%10%20%30%40% Total trials Recruiting share Neuren Pharmaceuticals LimitedAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAcera SurgicalAlign TechnologyAltruBioAlvernia University
Neuren Pharmaceuticals Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Neuren Pharmaceuticals Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Neuren Pharmaceuticals Limited page

10 registered trials is a research-attention snapshot, not an endorsement of Neuren Pharmaceuticals Limited or any single study.

  • 2 of Neuren Pharmaceuticals Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Phelan-McDermid Syndrome is the condition Neuren Pharmaceuticals Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Phelan-McDermid Syndrome trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Neuren Pharmaceuticals Limited pipeline card: 10 registered trials from official public datasets.Report a data error.